Chemotherapy-Induced Thrombosis: A Role for Microparticles and Tissue Factor?

ABSTRACT

Chemotherapy is an independent risk factor of thromboembolic events in cancer patients. Various pathogenetic mechanisms have been hypothesized in the past, but until now their individual contribution to the risk of thrombosis has been hardly investigated in clinical trials. In recent years, studies increasingly suggested an association between the prothrombotic state in cancer patients and circulating tissue factor–exposing microparticles. In this review, we discuss the roles of tissue factor and microparticles with regard to chemotherapy-induced hypercoagulability.

KEYWORDS

Cancer - chemotherapy - thrombosis - tissue factor - microparticles

REFERENCES

• 1 Otten H M, Mathijssen J, ten Cate H et al.. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon.  Arch Intern Med. 2004;  164 190-194
• 2 Sallah S, Wan J Y, Nguyen N P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics.  Thromb Haemost. 2002;  87 575-579
• 3 Khorana A A, Francis C W, Culakova E, Kuderer N M, Lyman G H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.  J Thromb Haemost. 2007;  5 632-634
• 4 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.  Thromb Haemost. 1997;  78 133-136
• 5 Dhami M S, Bona R D, Calogero J A, Hellman R M. Venous thromboembolism and high grade gliomas.  Thromb Haemost. 1993;  70 393-396
• 6 Numico G, Garrone O, Dongiovanni V et al.. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.  Cancer. 2005;  103 994-999
• 7 Khorana A A, Francis C W, Culakova E, Lyman G H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.  Cancer. 2005;  104 2822-2829
• 8 Levine M N, Gent M, Hirsh J et al.. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.  N Engl J Med. 1988;  318 404-407
• 9 Khorana A A, Kuderer N M, Culakova E, Lyman G H, Francis C W. Development and validation of a predictive model for chemotherapy-associated thrombosis.  Blood. 2008;  111 4902-4907
• 10 Lyman G H, Khorana A A, Falanga A et al.. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.  J Clin Oncol. 2007;  25 5490-5505
• 11 Paredes N, Xu L, Berry L R, Chan A K. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces.  Br J Haematol. 2003;  120 315-324
• 12 Aitokallio-Tallberg A, Viinikka L, Ylikorkala O. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment.  Br J Cancer. 1989;  60 785-788
• 13 Walsh J, Wheeler H R, Geczy C L. Modulation of tissue factor on human monocytes by cisplatin and adriamycin.  Br J Haematol. 1992;  81 480-488
• 14 Togna G I, Togna A R, Franconi M, Caprino L. Cisplatin triggers platelet activation.  Thromb Res. 2000;  99 503-509
• 15 Bertomeu M C, Gallo S, Lauri D, Levine M N, Orr F W, Buchanan M R. Chemotherapy enhances endothelial cell reactivity to platelets.  Clin Exp Metastasis. 1990;  8 511-518
• 16 Woodley-Cook J, Shin L Y, Swystun L, Caruso S, Beaudin S, Liaw P C. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway.  Mol Cancer Ther. 2006;  5 3303-3311
• 17 Feffer S E, Carmosino L S, Fox R L. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil.  Cancer. 1989;  63 1303-1307
• 18 Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin.  Cancer. 1990;  65 885-889
• 19 Liebman H A, Wada J K, Patch M J, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase.  Cancer. 1982;  50 451-456
• 20 Mewhort-Buist T A, Liaw P C, Patel S, Atkinson H M, Berry L R, Chan A K. Treatment of endothelium with the chemotherapy agent vincristine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma.  Thromb Res. 2008;  , in press
• 21 Oner A F, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase.  Leuk Lymphoma. 1999;  33 361-364
• 22 Lopez J A, Kearon C, Lee A Y. Deep venous thrombosis.  Hematology (Am Soc Hematol Educ Program). 2004;  1 439-456
• 23 Falati S, Gross P, Merrill-Skoloff G, Furie B C, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse.  Nat Med. 2002;  8 1175-1181
• 24 Giesen P L, Rauch U, Bohrmann B et al.. Blood-borne tissue factor: another view of thrombosis.  Proc Natl Acad Sci U S A. 1999;  96 2311-2315
• 25 Sturk-Maquelin K N, Nieuwland R, Romijn F P, Eijsman L, Hack C E, Sturk A. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo.  J Thromb Haemost. 2003;  1 1920-1926
• 26 Yu J L, Rak J W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells.  J Thromb Haemost. 2004;  2 2065-2067
• 27 Freyssinet J M. Cellular microparticles: what are they bad or good for?.  J Thromb Haemost. 2003;  1 1655-1662
• 28 Hron G, Kollars M, Weber H et al.. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.  Thromb Haemost. 2007;  97 119-123
• 29 Tesselaar M E, Romijn F P, Van Der Linden I K, Prins F A, Bertina R M, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.  J Thromb Haemost. 2007;  5 520-527
• 30 Zwicker J I, Kos C A, Johnston K A, Liebman H A, Furie B C, Furie B. Cancer-associated thrombosis: tissue factor-bearing microparticles are associated with an increased risk of venous thromboembolic events in cancer patients.  J Thromb Haemost. 2007;  5 , (abstract O-M-005)
• 31 Licciardello J T, Moake J L, Rudy C K, Karp D D, Hong W K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy.  Oncology. 1985;  42 296-300
• 32 Lechner D, Kollars M, Gleiss A, Kyrle P A, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity.  J Thromb Haemost. 2007;  5 2445-2452
• 33 Weber H, Lechner D, Kollars M, Eichinger S, Kyrle P A, Weltermann A. Shedding of procoagulant microparticles from tumor cells after chemotherapy.  Hämostaseologie. 2007;  01 , (abstract FV05)
• 34 Kim H K, Song K S, Park Y S, Kim C M, Lee K R. Method comparison of flow cytometric assay of platelet microparticles and changes of platelet microparticles during cancer chemotherapy.  Thromb Haemost. 2002;  87 547-548
• 35 Periard D, Boulanger C M, Eyer S et al.. Are circulating endothelial-derived and platelet-derived microparticles a pathogenic factor in the cisplatin-induced stroke?.  Stroke. 2007;  38 1636-1638
• 36 Simak J, Holada K, Vostal J G. Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin.  BMC Cell Biol. 2002;  3 11
• 37 Telgenhoff D J, Aggarwal S K, Johnson B N. Histochemical and morphological identification of Kupffer cells activated by cisplatin.  Anticancer Res. 1999;  19 1005-1010
• 38 Willekens F L, Werre J M, Kruijt J K et al.. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors.  Blood. 2005;  105 2141-2145
• 39 Falati S, Liu Q, Gross P et al.. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.  J Exp Med. 2003;  197 1585-1598
• 40 Levitan N, Dowlati A, Remick S C et al.. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.  Medicine (Baltimore). 1999;  78 285-291